What is HC Wainwright’s Estimate for ZNTL FY2025 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research note issued on Tuesday, November 11th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($1.78) per share for the year, up from their previous forecast of ($1.85). HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2025 earnings at ($0.37) EPS and FY2026 earnings at ($1.76) EPS.

A number of other analysts have also issued reports on ZNTL. Leerink Partners restated a “market perform” rating and issued a $2.00 price target on shares of Zentalis Pharmaceuticals in a report on Tuesday. Wedbush reiterated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Tuesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research report on Wednesday, October 8th. Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Finally, Morgan Stanley reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $5.03.

Zentalis Pharmaceuticals Stock Down 1.5%

Shares of ZNTL stock opened at $1.32 on Thursday. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $4.16. The stock has a market cap of $95.37 million, a P/E ratio of -0.64 and a beta of 1.87. The business has a fifty day simple moving average of $1.53 and a 200-day simple moving average of $1.45.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.12.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 150.6% in the 1st quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock valued at $4,244,000 after acquiring an additional 1,606,802 shares during the last quarter. Nuveen LLC bought a new position in Zentalis Pharmaceuticals during the first quarter worth $807,000. Tybourne Capital Management HK Ltd. boosted its holdings in Zentalis Pharmaceuticals by 53.7% in the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after purchasing an additional 516,666 shares during the period. GSA Capital Partners LLP increased its stake in Zentalis Pharmaceuticals by 275.9% during the first quarter. GSA Capital Partners LLP now owns 541,975 shares of the company’s stock valued at $862,000 after purchasing an additional 397,805 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Zentalis Pharmaceuticals during the first quarter worth $81,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.